Figure S2 (related to
The effects of mTORC1, Akt and PKC inhibition on neutrophil chemotaxis and cAMP production A. Effect of short-and long-term Rapamycin treatment on mTORC1 and mTORC2 function. Human blood neutrophils were treated with or without 100 nM Rapamycin for 30 min or 24 hrs, stimulated with 1 µM fMLP for 10 min and P-Akt Ser473 and P-p70SK Thr389 were determined by Western analyses using specific antibodies. Results are representative of three independent experiments. B. Inhibition of mTORC1 inhibits GM-CSF-induced neutrophil chemotaxis. Human blood neutrophils were treated with or without 100 nM Rapamycin for 30 min, 60 min or 24 h. 1x10 6 cells were loaded in the upper chamber of 5 m transwell chambers, attractants (1 µM fMLP or 10 ng/ml GM-CSF) were added to the lower chamber. Cells that migrated across the filter were counted after 1.5 hrs. Results represent the percent of migrating cell. Results show the average (+/-S.D.) of three independent experiments. * indicates p<0.01 compared to either the fMLP (left panel) or GM-CSF (right panel) group. C. Akt inhibitor VIII inhibits Akt function. Human blood neutrophils were treated with or without 10 µM Akt inhibitor VIII for 30 min, stimulated with 1 µM fMLP for 10 min and PAkt Ser473 and Thr308 were determined by Western analyses using specific antibodies. Results are representative of three independent experiments. D. Migration velocity (V) in m/min and chemotaxis index (CI) of Rapamycin, Akt inhibitor VIII or GO6976 treated and untreated neutrophils. * indicates p<0.01 compared to Vehicle. E. KD of Rictor inhibits fMLP-induced cAMP production. Differentiated cells were stimulated with 1 µM fMLP for indicated time and intracellular cAMP levels in WT, NS, and Rictor shRNA(2) were measured. Results represent the average (+/-S.D.) of three independent experiments. F. Inhibition of cPKC inhibits LTB 4 -induced cAMP production. Human blood neutrophils were treated with 10 µM Akt inhibitor VIII or 10 µM cPKC inhibitor GO6976 for 30 min. Cells were stimulated with 500 nM LTB 4 for 30 secs. Intracellular cAMP levels were measured before and after chemoattractant addition. Results represent the average (+/-S.D.) of three independent experiments. * indicates p<0.01 compared to the vehicle LTB 4 group. (1)). B. KD of AC9 inhibits fMLP-induced cAMP production. Differentiated cells were stimulated with 1 µM fMLP for indicated time and intracellular cAMP levels in WT, NS, and AC9 shRNA(2) cells were measured. Results represent the average (+/-S.D.) of three independent experiments. C. KD of AC9 inhibits LTB 4 -induced cAMP production. Differentiated cells were stimulated with 500 nM LTB 4 for 30 secs. Intracellular cAMP levels were measured before and after chemoattractant stimulation. SEM values are presented from six independent experiments. # indicates p<0.05 compared to buffer-treated NS shRNA group; * indicates p<0.01 compared to LTB 4 -treated NS shRNA group. D. Under-agarose chemotaxis assay of WT and NS shRNA cells. Differentiated cells were plated on either side of a well containing 500 nM fMLP. After 4 hrs, the wells were overlaid with phosphate buffer, and images were acquired using a Leica DM IL stereoscope. Results are representative of three independent experiments. E. Migration velocity (V) in m/min and chemotaxis index (CI) of Rictor shRNA and AC9 shRNA cells. Velocity measurements for AC9 and Rictor shRNA cells were not provided, as these cells did not effectively migrate. * indicates p<0.01 compared to NS shRNA.
Figure S4 (related to Figure 4) Characterization of AC9-Venus and AC3-eGFP cells
A. Bright field and fluorescent images depicting the cellular distribution of Venus, AC3-eGFP or AC9-Venus in undifferentiated cells. Both AC3-eGFP and AC9-Venus distributed to the plasma membrane in undifferentiated cells. B. AC9-Venus and AC3-eGFP cells express the expected 178 and 158 kDa fusion proteins. Cell lysates from undifferentiated cells were subjected to Western analyses using an antibody against GFP. We also established that the exogenous expression of either AC3 or AC9 did not alter the ability of PLB-985 cells to be differentiated into neutrophil-like cells (data not shown). C. AC9 KD does not alter AC3-eGFP expression. AC3-eGFP cells were infected with lentivirus expressing either pGIPZ NS or AC9-specific (#1) shRNAs plasmids. AC3 mRNA and AC9 mRNA level were measured by Real-time RT PCR. Results represent the average (+/-S.D.) of three independent experiments. * indicates p<0.01 compared to the WT group. D. Under agarose chemotaxis assay of Venus, AC3-eGFP or AC9-Venus cells. Differentiated cells were plated on either side of a well containing 500 nM LTB 4 . After 4 hrs, the wells were overlaid with phosphate buffer, and images were acquired using a Leica DM IL stereoscope. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES Materials
Diisopropyl fluorophosphate, f-Met-Leu-Phe, phenylmethanesulfonyl fluoride, polybrene, gelatin and fibronectin were purchased from Sigma (Saint Louis, MO). Lipofectamine was purchase from Invitrogen (Carlsbad, CA). Complete Protease Inhibitor Cocktail Tablets was from Roche Diagnostics (Indianapolis, IN). LTB 4 was purchase for Caymen Chemical (Ann Arbor, MI). Rabbit polyclonal antibodies against Akt, phosphorylated Akt (Thr-308 and Ser 473), phosphorylated p70S6K (Thr389), mTOR, myosin light chain 2, and phosphorylated myosin light chain 2 (Ser19) were from Cell Signaling Technology (Beverly, MA). Rabbit polyclonal antibodies against GFP were purchased from Covance (Berkeley, CA). Rictor antibody was purchased from Bethyl lab (Montgomery, TX). Mouse monoclonal antibody against RhoA was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). cAMP ELISA Kit was purchased from Cell Biolabs, Inc (San Diego, CA). CD11b APC antibody was purchase from BD Biosciences (San Jose, CA). Transwell chambers were purchased from Corning Life Scienes (Lowell, MA).
Construct and Transfection of PLB-985 Cells
The expression plasmids were transfected into packaging Phoenix cell lines using lipofectamine. Transiently produced virus was harvested after 48 or 72 hrs. PLB-985 cells were infected with the virus with fresh RPMI 160 culture medium containing 15 g/ml polybrene, and incubated for additional 48 hrs. Cells stably expressing the genes were selected in media containing 0.6 mg/ml of G-418. Stable clonal populations were generated after 14-21 days and maintained in the selection media. Stable AC9 KD and Rictor KD stable cells were generated using RNA interference technique.
Retroviral approach: The Venus gene was amplified from the pSC2 Venus and cloned at the 3' end of the AC9 cDNA. Similarly, e-GFP gene was amplified from pEGFPN1 and cloned at the 3' end of the AC3 cDNA. The resulting AC9-Venus and AC3-eGFP fusion was sequenced and cloned into the retroviral expression vector pMSCVneo. The DNA construct for the FRET B-domain sensor was previously generated in Dictyostelium (Bagorda et al., 2009 ) and subcloned into the retroviral expression vector pMSCVneo. Lentiviral approach: Undifferentiated PLB-985 cells were infected with pGIPZ lentiviruses (Open Biosystem) carrying the AC9 hairpin sequence (1) 5-TGCTGTTGACAGTGAGCGCGCAGATCGAAGAAGTCAGTATTAGTGAAGCCACAGA TGTAATACTGACTTCTTCGATCTGCTTGCCTACTGCCTCGGATTTC-3; AC9 hairpin sequence (2) 5-TGCTGTTGACAGTGAGCGCGCCCAGACAGTTCTGTATTAATAGTGAAGCCACAGAT GTATTAATACAGAACTGTCTGGGCATGCCTACTGCCTCGGA-3; the Rictor hairpin sequence (1) 5-TGCTGTTGACAGTGAGCGACCAGACCTCATGGATAATTATTAGTGAAGCCACAGAT GTAATAATTATCCATGAGGTCTGGCTGCCTACTGCCTCGGA-3; and the Rictor hairpin sequence (2) 5-TGCTGTTGACAGTGAGCGCCGTGATTCCAGATATACTAAATAGTGAAGCCACAGAT GTATTTAGTATATCTGGAATCACGTTGCCTACTGCCTCGGA-3 and selected in media containing 0.6 g/ml puromycin for 14-21days.
Isolation of Peripheral Blood Neutrophils
Heparinized whole blood was obtained by venipuncture from healthy donors following an Institutional Review Board-approved protocol. Neutrophils were isolated as described previously (Mahadeo et al., 2007) .
Immunofluorescence
Differentiated cells were allowed to adhere to gelatin-coated coverslips for 10 min and then uniformly stimulated with 1 µM fMLP. Cell were fixed with 4% paraformaldehyde for 10 min at RT, then washed with PBS and re-fixed with ice cold 100% methanol at -20 °C for 10 min. Then cells were permeabilized with 0.1% Triton at RT for 10 min and blocked with Rabbit IgG (dissolved in 2% BSA) for 30 min, followed by overnight incubation with appropriate primary antibodies at 4°C. After three successive washes in PBS, the cells were incubated with secondary antibody (Alexa Fluor 594 goat anti rabbit) for 1 hr, washed three times in PBS, and mounted on a glass slide. The cells were visualized using a Zeiss Axiovert 200 equipped with a PE ERS6FO UltraView Spinning Disk confocal system (Perkin Elmer).
cAMP measurements
Cells were differentiated for 5 days and starved for 24 hrs in serum reduced (0.2% FBS) differentiation medium, and washed three times in ice-cold mHBSS. 110 6 cells were lysed before and after chemoattractant stimulation, cAMP concentrations were measured using the Cell Biolabs chemiluminescent ELISA kit.
F-actin polymerization and cellular polarization
Differentiated cells (210 6 cells /ml) in mHBSS were stimulated with 1M fMLP. At the indicated time points, cells were harvested, fixed with ice-cold 4% paraformaldehyde for 10 min, permeabilized with Solution I (0.2% BSA, 0.2% Triton-X100 in PBS) and stained with rhodamine-phalloidin. Cells were analyzed using a flow cytometer for F-actin content. To determine cell polarization, cells were plated on fibronectin-coated 8 well Lab-Tek chamber slides and stimulated with 1M fMLP. At the indicated time points, cells were fixed with ice-cold 4% paraformaldehyde for 10 min, permeabilized, stained with rhodamine-phalloidin and analyzed by confocal microscope. For each experiment, 50 cells per time point were analyzed.
Quantitative RT-PCR
Total RNA from cells was extracted using TRIzol® Reagent (Invitrogen, Carlsbad, CA) and quantitated by spectrophotometer. Reverse transcription of RNA to cDNA was performed using iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA). AC9, AC3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used for quantitative PCR. Primer sequences used for PCR are as follows: AC9 forward primer: 5-GCCACCGCAAAATACTTAGAT-3, reverse primer: 5-TGTGAGCCGTCAATGACCTCA-3; AC3 forward primer: 5-TCATCTCCGTGGTCTCCTGGT-3, reverse primer: 5-GGGCCTCCAGGAAGGCCTTGC-3; GAPDH forward primer: 5-TGCACCACC AACTGCTTAGC-3, reverse primer: 5-GGCATGGACTGTGGTCATGAG-3. 40 cycles of 95 °C for 15 s, 55 °C for 30 s, 72 °C for 30 s. Real-time PCR was performed with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) on an ABI 7700 Sequence Detection System (Applied Biosystems). Samples were run in triplicates and normalized to GAPDH expression levels.
RhoA-GTP Pull-Down Assay
Activation of RhoA was determined by a modified method described by Benard and Bokoch (Benard and Bokoch, 2002) . Differentiated PLB-985 cells were washed twice with mHBSS, added to a 12-well, and allowed to adhere for 10 min at 37°C. After stimulation with or without fMLP (1 M) for the indicated times, cells were immediately lysed in ice-cold lysis buffer (50 mM Tris (pH 7.2), 1% Triton X-100, 0.1% SDS, 500 mM NaCl, 10 mM MgCl2, 1 mM diisopropyl fluorophosphates, Protease Inhibitor cocktail, 1 mM PMSF) and maintained on ice for 20 min. After centrifugation at 14,000 rpm for 10 min, the supernatant fractions were incubated with 0.1 ml of Rhotekin RBD-agarose beads (which bind RhoA-GTP) for 1 hr at 4°C, followed by three washes with Tris buffer (50 mM) containing 1% Triton X-100, 150 mM NaCl, 10 mM MgCl 2 , 1 mM diisopropyl fluorophosphate, 0.1 mM PMSF, and Protease Inhibitor cocktail. Proteins bound to the beads were eluted in 2X Laemmli sample buffer and subjected to Western blot analysis by using a mouse monoclonal antibody specific for RhoA.
